Barrett Elizabeth A.
Known title: Chief Executive OfficerCIK: 0001764157
Associated companies
Transaction History
| URGN | ▲ Buy | Option Exercise | 13,333 | — | 1/31/2023 | View on chart |
| URGN | ▲ Buy | Option Exercise | 5,000 | — | 1/31/2023 | View on chart |
| URGN | ▲ Buy | Option Exercise | 5,000 | — | 1/31/2022 | View on chart |
| URGN | ▼ Sell | Open Market | 2,235 | $17K | 1/31/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 13,333 | — | 1/31/2022 | View on chart |
| URGN | ▼ Sell | Open Market | 5,960 | $45K | 1/31/2022 | View on chart |
| URGN | ▼ Sell | Open Market | 46,968 | $430K | 1/4/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 105,689 | — | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock
UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.